Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-612
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Partially revisedNet Sales-37.1%
基準 1,651Target1,038million
Operating profit-639.5%
基準 129Target-696million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
What happened to the previous planRevenue 977; operating loss 295 → Actual: revenue 323; operating loss 748-23.4%Calculated from the two disclosed figures
Key initiatives
01Improving Awareness
02Indication expansion
03Increase the number of treatment facilities
04Overseas Expansion
05Cost reduction measures
06Strengthening Competitiveness
Non-financial targetsIndicator name BNCT-insured treatment facilities / Target value Increase of 4 facilities / Timing Not disclosed
Size of the Target MarketGlobal BNCT market $2.19 billion in 2030 / Europe $320 million in 2030 / Asia $1.29 billion in 2030 / United States $540 million in 2030 / Source QYResearch：Global Boron Neutron Capture Therapy (BNCT) Market Research Report 2024
Risks identified by the company
Insufficient awareness
Limited indications
Small number of treatment facilities
Treatment limited to Japan
Downward pressure on drug prices
Entry of new competitors
Reason for revision or withdrawal
The medium-term plan was revised following lower sales caused by delays in starting treatment on Hainan Island and higher costs for rebuilding a stable supply structure after the contract manufacturer's production stoppage.
| Item | Details |
|---|---|
| Plan name | Medium-Term Plan |
| Plan period | Fiscal years ending March 2025 to March 2027 |
| Progress against the plan | Partially revised |
| Sales Target | ¥1,651 million → ¥1,038 million |
| Operating profit target | ¥129 million → ¥-696 million |
| Non-financial targets | Indicator name BNCT-insured treatment facilities / Target value Increase of 4 facilities / Timing Not disclosed |
| Key initiatives | Improving Awareness, Indication expansion, Increase the number of treatment facilities, Overseas Expansion, Cost reduction measures, Strengthening Competitiveness |
| Results under the previous plan | Revenue 977; operating loss 295 → Actual: revenue 323; operating loss 748 |
| Reason for revision or withdrawal | The medium-term plan was revised following lower sales caused by delays in starting treatment on Hainan Island and higher costs for rebuilding a stable supply structure after the contract manufacturer's production stoppage. |
| Size of the Target Market | Global BNCT market $2.19 billion in 2030 / Europe $320 million in 2030 / Asia $1.29 billion in 2030 / United States $540 million in 2030 / Source QYResearch：Global Boron Neutron Capture Therapy (BNCT) Market Research Report 2024 |
| Risks identified | Insufficient awareness, Limited indications, Small number of treatment facilities, Treatment limited to Japan, Downward pressure on drug prices, Entry of new competitors |
Items this document does not state (14)
Operating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetPlan assumptionsDate of board resolutionPublication date
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The medium-term plan was revised following lower sales caused by delays in starting treatment on Hainan Island and higher costs for rebuilding a stable supply structure after the contract manufacturer's production stoppage.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.